Dermatologic Adverse Events Associated with Immune Checkpoint Inhibitors in Melanoma: A Network Meta-Analysis of Randomized Trials
Published: 7 July 2022| Version 1 | DOI: 10.17632/fj3422ckc9.1
eFigure 1 Flowchart of trial selection eTable 1. Trial characteristics eTable 2. P-scores and best safety rankings for rash and pruritus in network meta-analyses. The P-score measures the extent of certainty that a treatment is better than another treatment, averaged over all competing treatments; a greater P-score indicates a higher likelihood of being the treatment with best safety for rash/pruritus.